Antisense and RNAi: powerful tools in drug target discovery and validation.
Drug target discovery and validation are complex processes that require significant resource investments and impose a substantial economic burden on the pharmaceutical industry. Technologies that accelerate or enhance the precision of target selection are, therefore, in high demand. Traditional antisense and RNA interference (RNAi) technologies are powerful tools with applications in multiple phases of drug target discovery and validation. These approaches elicit potent and highly selective cleavage of a target mRNA, permitting evaluation of the role of the corresponding protein based on a loss-of-function phenotype. Incorporation of these technologies into high-throughput screens, in vitro biological assays and in vivo disease models provides valuable insight into gene function. Efforts are also underway to develop these agents as drugs. This review presents recent studies involving antisense and RNAi, and discusses how these technologies are facilitating target selection at various stages of the drug development process.
Lavery
Karen S
KS
Sequitur Inc., 14 Tech Circle, Natick, MA 01060, USA.
King
Thomas H
TH
D000818:Animals; D001681:Biological Assay; D016503:Drug Delivery Systems; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D006801:Humans; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage / Q000627:therapeutic use; D034622:RNA Interference; D016372:RNA, Antisense
D016376:Oligonucleotides, Antisense; D016372:RNA, Antisense